Team:Cambridge/Quiescence

From 2010.igem.org

(Difference between revisions)
(Regulator of cell division RNA)
Line 13: Line 13:
A new approach to making a quiescence switch would be to control the functionality of the folded RNA instead of its transcription, which proved to be problematic. Ideally the bacteria would grow in the lab or a vat in the presence of a ligand but would stop growing without dying, as soon as the ligand is removed. Thus if the engineered bacteria escaped into the wild they would stop growing very quickly as the ligand is diluted.  
A new approach to making a quiescence switch would be to control the functionality of the folded RNA instead of its transcription, which proved to be problematic. Ideally the bacteria would grow in the lab or a vat in the presence of a ligand but would stop growing without dying, as soon as the ligand is removed. Thus if the engineered bacteria escaped into the wild they would stop growing very quickly as the ligand is diluted.  
-
We hope to achieve this by rationally designing a gene for an RNA that folds into a non-functional shape. The structure will include a hammerhead ribozyme domain that will hopefully cleave itself in vivo to release the functional Rcd RNA.
+
We hope to achieve this by rationally designing a gene for an RNA that folds into a non-functional shape. The structure will include a hammerhead ribozyme domain that will hopefully cleave itself in vivo to release the functional Rcd RNA. In order to control this cleavage, the final construct would include an aptamer, which is an RNA structure able to bind a specific compound. This would create an allosteric ribozyme.
-
The project would involve synthesising lots of different constructs (which are all mercifully short) and testing their functionality and sensitivity. The result would be a fairly short, but quite versatile BioBrick.
+
The project would involve synthesising different constructs (which are all mercifully short) and testing their functionality and sensitivity. The result would be a fairly short, but quite versatile BioBrick.
-
According to mFold and CLC workbench, [https://2010.igem.org/Team:Cambridgee/Quiescence/Sequences the sequence we designed] folds into a non-functional form, as expected. This sequence does not include the aptamer yet.  
+
According to mFold and CLC workbench, [https://2010.igem.org/Team:Cambridgee/Quiescence/Sequences the sequence we designed] folds into a non-functional form, as expected. The predicted secondary structure is depicted on the left. This sequence does not include the aptamer yet. We are now investigating aptamers binding theophylline. This compound has been very described in the context of allosteric ribozymes, is easily available, non-toxic in low concentrations (naturally found in black tea), and non-native to bacteria.
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713350/ Smolke et al. 2009] gives a nice review of aptamer activated hammerhead ribozymes and other functional RNA structures. More information on ribozymes (self- or trans-cleaving) can be found in [http://lim.fcien.edu.uy/tallerbm/pdf/2.%20Serganov%202007%20Nature%20Rev%20Gen.pdf Serganov and Patel 2007].  
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713350/ Smolke et al. 2009] gives a nice review of aptamer activated hammerhead ribozymes and other functional RNA structures. More information on ribozymes (self- or trans-cleaving) can be found in [http://lim.fcien.edu.uy/tallerbm/pdf/2.%20Serganov%202007%20Nature%20Rev%20Gen.pdf Serganov and Patel 2007].  
 +
 +
 +
==Intellectual Property==
Using Rcd in the H-NS mutant to induce quiescence in E.coli is the Intellectual Property of Cambridge Microbial technologies. Dr Summers has been very supportive and we are going to continue the project. However, the legal issues have not been completely resolved yet. We still need to talk to Robert Hulme, the co-holder of the patent.  
Using Rcd in the H-NS mutant to induce quiescence in E.coli is the Intellectual Property of Cambridge Microbial technologies. Dr Summers has been very supportive and we are going to continue the project. However, the legal issues have not been completely resolved yet. We still need to talk to Robert Hulme, the co-holder of the patent.  

Revision as of 11:41, 28 July 2010